Skip to main content
. Author manuscript; available in PMC: 2013 Jun 10.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Jun 22;4(11):1816–1824. doi: 10.1158/1940-6207.CAPR-11-0130

Figure 1. EZH2 expression and OSCC development.

Figure 1

(A) Immunohistochemical expression of EZH2 in OL tissue samples: Nuclear expression of EZH2 strongly correlated with the grade of dysplasia, the grade of dysplasia increasing from weak (i), moderate (ii) to strong (iii) (40x). (B) Kaplan Meier curves of OSCC-free survival based on EZH2 expression.